Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- KANT
- Price
- 0.29
- Stock movement up
- +0.02 (7.78%)
- Company name
- Kineta, Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.57M
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -46.11%
- 3 year return
- -70.19%
- 5 year return
- -72.97%
- 10 year return
- -
Last updated: 2025-08-27
DIVIDENDS
KANT does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.28 |
| Daily high | 0.29 |
| Daily low | 0.28 |
| Daily Volume | 41K |
| All-time high | 2814.00 |
| 1y analyst estimate | - |
| Beta | -3.66 |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | 19 Dec 2022 |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| KANT | S&P500 | |
| Current price drop from All-time high | -99.99% | -3.04% |
| Highest price drop | -99.99% | -56.47% |
| Date of highest drop | 2 Jun 2025 | 9 Mar 2009 |
| Avg drop from high | -85.62% | -11.04% |
| Avg time to new high | 118 days | 12 days |
| Max time to new high | 2270 days | 1805 days |
COMPANY DETAILS
Marketcap
3.57M
Marketcap category
Small-cap
Description
Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients' lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. It has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., Merck &Co., Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Mercer Island, Washington.
Employees
4
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner